Trespidi Gabriele, Scoffone Viola Camilla, Barbieri Giulia, Marchesini Federica, Abualsha'ar Aseel, Coenye Tom, Ungaro Francesca, Makarov Vadim, Migliavacca Roberta, De Rossi Edda, Buroni Silvia
Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Unit of Microbiology and Clinical Microbiology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy.
Pathogens. 2021 Jul 13;10(7):886. doi: 10.3390/pathogens10070886.
infections represent a great concern due to their versatility and involvement in different types of diseases. The shortage of available clinical options, especially to treat multiresistant strains, makes the discovery of new effective compounds essential. Here we describe the activity of the previously described cell division inhibitor C109 against methicillin-sensitive and -resistant strains. Antibiofilm activity was assessed using microtiter plates, confocal microscopy, and in an in vitro biofilm wound model. The ability of C109 to block FtsZ GTPase activity and polymerization was tested in vitro. Altogether, the results show that the FtsZ inhibitor C109 has activity against a wide range of strains and support its use as an antistaphylococcal compound.
由于感染具有多样性且涉及不同类型的疾病，因此备受关注。可用的临床治疗选择短缺，尤其是针对多重耐药菌株的治疗，这使得发现新的有效化合物至关重要。在此，我们描述了先前报道的细胞分裂抑制剂C109对甲氧西林敏感和耐药菌株的活性。使用微量滴定板、共聚焦显微镜以及体外生物膜伤口模型评估了其抗生物膜活性。在体外测试了C109阻断FtsZ GTPase活性和聚合的能力。总体而言，结果表明FtsZ抑制剂C109对多种菌株具有活性，并支持将其用作抗葡萄球菌化合物。
